Literature DB >> 26918415

First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 5: recipient monitoring and response plan for preventing disease transmission.

Joachim Denner1, Ralf R Tönjes2, Yasu Takeuchi3, Jay Fishman4, Linda Scobie5.   

Abstract

Xenotransplantation of porcine cells, tissues, and organs may be associated with the transmission of porcine microorganisms to the human recipient. A previous, 2009, version of this consensus statement focused on strategies to prevent transmission of porcine endogenous retroviruses (PERVs). This version addresses potential transmission of all porcine microorganisms including monitoring of the recipient and provides suggested approaches to the monitoring and prevention of disease transmission. Prior analyses assumed that most microorganisms other than the endogenous retroviruses could be eliminated from donor animals under appropriate conditions which have been called "designated pathogen-free" (DPF) source animal production. PERVs integrated as proviruses in the genome of all pigs cannot be eliminated in that manner and represent a unique risk. Certain microorganisms are by nature difficult to eliminate even under DPF conditions; any such clinically relevant microorganisms should be included in pig screening programs. With the use of porcine islets in clinical trials, special consideration has to be given to the presence of microorganisms in the isolated islet tissue to be used and also to the potential use of encapsulation. It is proposed that microorganisms absent in the donor animals by sensitive microbiological examination do not need to be monitored in the transplant recipient; this will reduce costs and screening requirements. Valid detection assays for donor and manufacturing-derived microorganisms must be established. Special consideration is needed to preempt potential unknown pathogens which may pose a risk to the recipient. This statement summarizes the main achievements in the field since 2009 and focus on issues and solutions with microorganisms other than PERV.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CRISPR/Cas; designated pathogen-free status; disease transmission; hepatitis E virus; infectious disease; islet xenotransplantation; porcine endogenous retrovirus; type 1 diabetes; xenozoonoses

Mesh:

Year:  2016        PMID: 26918415     DOI: 10.1111/xen.12227

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  12 in total

Review 1.  The origin of porcine endogenous retroviruses (PERVs).

Authors:  Joachim Denner
Journal:  Arch Virol       Date:  2021-02-06       Impact factor: 2.574

2.  Absence of interaction between porcine endogenous retrovirus and porcine cytomegalovirus in pig-to-baboon renal xenotransplantation in vivo.

Authors:  Jay A Fishman; David H Sachs; Kazuhiko Yamada; Robert A Wilkinson
Journal:  Xenotransplantation       Date:  2018-04-06       Impact factor: 3.907

Review 3.  Pig-to-Primate Islet Xenotransplantation: Past, Present, and Future.

Authors:  Zhengzhao Liu; Wenbao Hu; Tian He; Yifan Dai; Hidetaka Hara; Rita Bottino; David K C Cooper; Zhiming Cai; Lisha Mou
Journal:  Cell Transplant       Date:  2017-02-03       Impact factor: 4.064

4.  Long-term safety outcome of systemic immunosuppression in pig-to-nonhuman primate corneal xenotransplantation.

Authors:  Se Hyun Choi; Chang Ho Yoon; Hyun Ju Lee; Hong Pyo Kim; Jong Min Kim; Jeong-Hwan Che; Kyoung Min Roh; Hyuk Jin Choi; Jiyeon Kim; Eung Soo Hwang; Chung-Gyu Park; Mee Kum Kim
Journal:  Xenotransplantation       Date:  2018-07       Impact factor: 3.907

5.  Xenotransplantation: Progress Along Paths Uncertain from Models to Application.

Authors:  Jeffrey L Platt; Marilia Cascalho; Jorge A Piedrahita
Journal:  ILAR J       Date:  2018-12-31

Review 6.  Xenotransplantation: past, present, and future.

Authors:  Burcin Ekser; Ping Li; David K C Cooper
Journal:  Curr Opin Organ Transplant       Date:  2017-12       Impact factor: 2.640

7.  Xenoantigen Deletion and Chemical Immunosuppression Can Prolong Renal Xenograft Survival.

Authors:  Andrew B Adams; Steven C Kim; Gregory R Martens; Joseph M Ladowski; Jose L Estrada; Luz M Reyes; Cindy Breeden; Allison Stephenson; Devin E Eckhoff; Matt Tector; Alfred Joseph Tector
Journal:  Ann Surg       Date:  2018-10       Impact factor: 12.969

Review 8.  Gene Editing, Gene Therapy, and Cell Xenotransplantation: Cell Transplantation Across Species.

Authors:  Nizar I Mourad; Pierre Gianello
Journal:  Curr Transplant Rep       Date:  2017-07-21

9.  A comprehensive microbiological safety approach for agarose encapsulated porcine islets intended for clinical trials.

Authors:  Lawrence S Gazda; James Collins; Archie Lovatt; Robert W Holdcraft; Merribeth J Morin; Daniel Galbraith; Melanie Graham; Melissa A Laramore; Christine Maclean; John Black; Euan W Milne; Douglas G Marthaler; Horatiu V Vinerean; Michelle M Michalak; Deborah Hoffer; Steven Richter; Richard D Hall; Barry H Smith
Journal:  Xenotransplantation       Date:  2016-11-11       Impact factor: 3.907

Review 10.  New Phase of Growth for Xenogeneic-Based Bioartificial Organs.

Authors:  Zorina Pitkin
Journal:  Int J Mol Sci       Date:  2016-09-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.